↓ Skip to main content

Oncotarget

Paradox breaker BRAF inhibitors have comparable potency and MAPK pathway reactivation to encorafenib in BRAF mutant colorectal cancer

Overview of attention for article published in Oncotarget, August 2020
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (90th percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

news
2 news outlets
blogs
1 blog
twitter
5 X users
facebook
1 Facebook page

Citations

dimensions_citation
10 Dimensions

Readers on

mendeley
18 Mendeley
Title
Paradox breaker BRAF inhibitors have comparable potency and MAPK pathway reactivation to encorafenib in BRAF mutant colorectal cancer
Published in
Oncotarget, August 2020
DOI 10.18632/oncotarget.27681
Pubmed ID
Authors

Oliver J. Pickles, Aneta Drozd, Louise Tee, Andrew D. Beggs, Gary W. Middleton

X Demographics

X Demographics

The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 18 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 18 100%

Demographic breakdown

Readers by professional status Count As %
Professor > Associate Professor 4 22%
Student > Ph. D. Student 3 17%
Student > Bachelor 2 11%
Student > Postgraduate 2 11%
Student > Master 1 6%
Other 2 11%
Unknown 4 22%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 6 33%
Medicine and Dentistry 4 22%
Chemistry 1 6%
Agricultural and Biological Sciences 1 6%
Unknown 6 33%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 27. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 October 2020.
All research outputs
#1,258,448
of 23,232,430 outputs
Outputs from Oncotarget
#570
of 14,367 outputs
Outputs of similar age
#36,380
of 398,890 outputs
Outputs of similar age from Oncotarget
#26
of 52 outputs
Altmetric has tracked 23,232,430 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 14,367 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.7. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 398,890 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 52 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.